Insights into the treatment of patients with FLT3-mutated AML & the role of maintenance therapy

Insights into the treatment of patients with FLT3-mutated AML & the role of maintenance therapyПодробнее

The management of R/R FLT3-mutated AMLПодробнее

Improving treatment approaches for FLT3-mutated AML: insights into the Optimise-FLT3 trialПодробнее

Finding the Key to Better Outcomes in FLT3-Mutated AMLПодробнее

Insights into the future of AML therapy: the increasing use of targeted agentsПодробнее

Gilteritinib maintenance after allogeneic transplantation in FLT3-mutated AMLПодробнее

Patient-reported outcomes in FLT3-mutated AML patients treated with gilteritinib plus azacitidineПодробнее

New Findings and Improved Outcomes in the Treatment of AMLПодробнее

An insight into MRD monitoring and MRD-driven treatment in AMLПодробнее

Maintenance therapy in AML: agents under investigation and future outlooksПодробнее

Optimizing the use of FLT3 inhibitors in AML: sequencing, post-transplant maintenance & moreПодробнее

FLT3-Mutated AML: Early Aggressive Therapy vs TransplantПодробнее

FLT3 inhibitors – an ideal strategy for treating FLT3-mutated AMLПодробнее

COSTEM AML highlights: SCT & MRD status, sorafenib maintenance & gilteritinib in FLT3+ AMLПодробнее

Treatment avenues for patients with R/R FLT3-mutated AML: optimizing FLT3 inhibitorsПодробнее

Role of FLT3 inhibitors as maintenance following transplant in AMLПодробнее

FLT3 inhibitors as maintenance therapy in AMLПодробнее

Midostaurin: a step forward in the treatment of FLT3-mutated AMLПодробнее

Gilteritinib Relapse Leads to Loss of FLT3-TKD Mutation in Patient With AMLПодробнее

How the AML treatment landscape has evolved with the use of novel combination therapiesПодробнее